Nicox SA (ALCOX)

Currency in EUR
0.484
+0.009(+1.89%)
Closed·
ALCOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4600.488
52 wk Range
0.2000.650
Key Statistics
Prev. Close
0.475
Open
0.473
Day's Range
0.46-0.488
52 wk Range
0.2-0.65
Volume
825.19K
Average Volume (3m)
673.76K
1-Year Change
58.0065%
Book Value / Share
-0.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALCOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.500
Upside
+209.92%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Nicox SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Nicox Company Profile

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

Employees
5
Market
France

Compare ALCOX to Peers and Sector

Metrics to compare
ALCOX
Peers
Sector
Relationship
P/E Ratio
−1.6x−3.9x−0.6x
PEG Ratio
-0.100.00
Price/Book
−8.9x2.0x2.6x
Price / LTM Sales
12.9x27.7x3.3x
Upside (Analyst Target)
209.9%129.7%44.9%
Fair Value Upside
Unlock4.9%5.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.500
(+209.92% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.04 / -0.04
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Nicox (ALCOX) Income Statement & Profits

People Also Watch

6.70
ADOC
-2.47%
4.855
ALMDT
-6.09%
23.04
MEDCL
-4.16%
61.30
ALSTI
-3.62%

FAQ

What Is the Nicox (ALCOX) Share Price Today?

The Nicox stock price today is 0.484 EUR.

What Stock Exchange Does Nicox (ALCOX) Trade On?

Nicox is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Nicox?

The stock symbol (also called a 'ticker') for Nicox is "ALCOX."

What Is the Current Nicox Market Cap?

As of today, Nicox market cap is 42.610M EUR.

What Is Nicox's (ALCOX) Earnings Per Share (TTM)?

The Nicox EPS is currently -0.373 (Trailing Twelve Months).

When Is the Next Nicox Earnings Date?

Nicox's next earnings report will be released on 30/04/2026.

Is ALCOX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nicox moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nicox Stock Split?

Nicox has split 4 times. (See the ALCOX stock split history page for full effective split date and price information.)

How Many Employees Does Nicox Have?

Nicox has 5 employees.

What is the current trading status of Nicox (ALCOX)?

As of 01/03/2026, Nicox (ALCOX) is trading at a price of 0.484 EUR, with a previous close of 0.475 EUR. The stock has fluctuated within a day range of 0.460 EUR to 0.488 EUR, while its 52-week range spans from 0.200 EUR to 0.650 EUR.

What Is Nicox (ALCOX) Price Target According to Analysts?

The average 12-month price target for Nicox is 1.500 EUR, with a high estimate of 1.5 EUR and a low estimate of 1.5 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +209.92% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.